New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

Preview

来源: PMLiVE

The University of Glasgow and the NHS Greater Glasgow and Clyde have launched a mid-stage study to evaluate a new drug combination as a first-line treatment for patients living with metastatic pancreatic cancer.

As part of the Precision-Panc Platform, the phase 2 PRIMUS-006 study will evaluate Eli Lilly and Genentech’s Gemzar (gemcitabine) in combination with Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Immodulon Therapeutics’ investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).

Currently the tenth most common cancer in the UK, pancreatic cancer is responsible for more than 10,000 new cases every year.

Often fatal, PDAC is commonly found too late and does not respond well to treatments.

Co-ordinated by the Glasgow Oncology Clinical Trials Unit, the new combination therapy will be evaluated in up to 50 patients diagnosed with metastatic PDAC who may not be able to receive current combination chemotherapy from up to 20 hospital sites in the UK.

The chemotherapy drug Gemzar is indicated as a first-line treatment for a variety of cancers, including bladder, breast, pancreas, ovary and non-small-cell lung cancer, while Merck’s T-cell checkpoint inhibitor is used in cancer immunotherapy for multiple cancers, including melanoma, lung cancer, cervical cancer and certain types of breast cancer.

Immodulon’s investigational IMM-101 is an immunomodulatory drug containing heat-killed, whole-cell Mycobacterium obuense, which is currently being evaluated in chemotherapy.

Professor David Chang, chief investigator and professor, surgical oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow and Glasgow Royal Infirmary, commented: “The… PRIMUS-006 study is an important milestone in the pursuit to develop new treatment options to improve the overall outcomes in patients diagnosed with pancreatic cancer.”

Most recently, Merck’s Keytruda received approval from the US Food and Drug Administration in combination with carboplatin and paclitaxel, and then as a single agent, to treat adults with primary, advanced or recurrent endometrial carcinoma.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。